Content about Sanofi US

September 16, 2013

Sanofi US and its consumer health business Chattem on Monday unveiled plans to re-introduce the iconic Rolaids heartburn-relief brand to the U.S. market.

PARIS — Sanofi US and its consumer health business Chattem on Monday unveiled plans to re-introduce the iconic Rolaids heartburn-relief brand to the U.S. market. The brand returns after a three-year hiatus in the marketplace and follows Chattem's acquisition of Rolaids earlier this year.  

August 1, 2013

Sanofi Wednesday evening announced that the Food and Drug Administration's Nonprescription Drugs Advisory Committee voted 10-6 in favor of its switch application of the nasal corticosteroid Nasacort AQ. Two committee members abstained.

SILVER SPRING, Md. — Sanofi Wednesday evening announced that the Food and Drug Administration's Nonprescription Drugs Advisory Committee voted 10-6 in favor of its switch application of the nasal corticosteroid Nasacort AQ. Two committee members abstained. 

February 12, 2013

The Colon Cancer Challenge Foundation, a nonprofit organization dedicated to reducing colorectal cancer incidence and death throughout the United States, presented Sanofi with its annual Blue Star Corporate Award.

NEW YORK — Sanofi US was named corporate partner of the year by the Colon Cancer Challenge Foundation (CCCF), a nonprofit organization dedicated to reducing colorectal cancer incidence and death throughout the United States, and presented with CCCF's annual Blue Star Corporate Award.

August 13, 2012

The Food and Drug Administration has approved a voice-guided injection device made by Sanofi for severe allergic reactions, the drug maker said Monday.

PARIS — The Food and Drug Administration has approved a voice-guided injection device made by Sanofi for severe allergic reactions, the drug maker said Monday.

The French drug maker announced the approval of Auvi-Q (epinephrine), calling it the first epinephrine auto-injector with audio and visual cues that guides users through the injection process. Sanofi US licensed the North American commercialization rights to Auvi-Q from Intelliject, which has retained commercialization rights for the rest of the world.